Cognition Therapeutics Schedules FDA Type C Meeting for Zervimesine
PURCHASE, N.Y. — September 29, 2026 Cognition Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) Division...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PURCHASE, N.Y. — September 29, 2026 Cognition Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) Division...
HYOGO, Japan — September 28, 2026 JCR Pharmaceuticals Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare...
HYOGO, Japan, July 21, 2026 JCR Pharmaceuticals announced that the United Arab Emirates (UAE) has granted marketing authorization for...
NEWTON, Mass., July 7, 2026 Acumen Pharmaceuticals announced that it will present three scientific studies at the Alzheimer’s Association...
HYOGO, Japan, June 8, 2026 JCR Pharmaceuticals Co., Ltd. announced new clinical findings from its J-Brain Cargo® blood-brain barrier...
MILAN, Italy & HYOGO, Japan | December 24, 2025 — Italfarmaco and JCR Pharmaceuticals have announced a landmark commercialisation...
